Experimental Oncology Group

Home | Research & Innovation | Scientific Programmes | Molecular Oncology Programme | Experimental Oncology Group

Staff Scientists

  • Matthias Drosten
  • Raquel García
  • Carmen Guerra
  • Monica Musteanu

Post-Doctoral Fellows

  • Sara García
  • Carolina Navas
  • Guillem Paniagua

Graduate Students

  • Laura De Esteban
  • Fernando Fernández
  • Jing Li
  • Vasiliki Liaki
  • Lucía Morales
  • Marina Salmón
  • Manuel Sanclemente

Technicians

  • Irene de Diego
  • Mª Carmen González
  • Patricia Teresa Guerra
  • Silvia Jiménez
  • Anna Köck
  • Marta San Román
  • Raquel Villar

KRAS oncogenes have been identified in one fifth of all human cancers. Yet, no selective inhibitors have been approved so far. Moreover, attempts to block KRAS oncogenic activity with selective inhibitors of KRAS signalling pathways have failed so far due to unacceptable toxicities. In our laboratory, we have continued our quest to validate therapeutic targets for KRAS driven lung and pancreatic tumours using a new generation of genetically engineered mouse tumour models that allow us to evaluate their anti-tumour properties as well as their potential toxic effects in tumour-bearing mice. These studies have allowed the identification of RAF1 as the only target within the MAPK signalling pathway capable of inducing significant tumour regressions in advanced KRAS/ TRP53 mutant tumours without inducing major toxicities. We are now focusing our research interests on: (i) devising therapeutic strategies to selectively targeting RAF1 and (ii) identifying additional targets that may cooperate with RAF1 inhibition, with the ultimate goal of translating these results to the clinic.

Publications

Up